Altium Capital Management LLC Raises Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Altium Capital Management LLC increased its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 2.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,395,000 shares of the biotechnology company's stock after buying an additional 35,000 shares during the period. ADMA Biologics accounts for 6.8% of Altium Capital Management LLC's portfolio, making the stock its 2nd largest position. Altium Capital Management LLC owned approximately 0.59% of ADMA Biologics worth $23,924,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in ADMA Biologics by 1.3% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company's stock valued at $865,000 after acquiring an additional 645 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its stake in ADMA Biologics by 1.3% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company's stock valued at $954,000 after acquiring an additional 700 shares during the period. Summit Investment Advisors Inc. grew its stake in shares of ADMA Biologics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company's stock worth $404,000 after acquiring an additional 746 shares during the period. Mutual of America Capital Management LLC raised its holdings in shares of ADMA Biologics by 2.1% during the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company's stock valued at $614,000 after purchasing an additional 751 shares during the last quarter. Finally, Maryland State Retirement & Pension System boosted its holdings in ADMA Biologics by 1.1% in the fourth quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company's stock worth $1,365,000 after purchasing an additional 897 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Price Performance

ADMA traded up $1.46 during trading on Tuesday, hitting $21.10. 1,247,591 shares of the company traded hands, compared to its average volume of 3,616,432. The stock's 50-day simple moving average is $18.33 and its two-hundred day simple moving average is $18.21. ADMA Biologics, Inc. has a 1 year low of $6.19 and a 1 year high of $23.64. The company has a market cap of $4.99 billion, a PE ratio of 75.26 and a beta of 0.53. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.